Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Manuel Hidalgo Medina, a director of Guardant Health, Inc. (GH), reported transactions dated 09/17/2025 showing the acquisition of 232 restricted stock units (RSUs) at $0 pursuant to vesting (Transaction Code M). The Form 4 shows 1,083 shares of common stock held following a separate non-derivative entry and 7,889 shares beneficially owned following the reported derivative transactions. The filing notes the RSU award was granted on July 17, 2024 and vests over four years: 25% vested at the one-year anniversary and the remaining 75% vests monthly over the following three years. The form is signed by an attorney-in-fact on 09/18/2025.
Tariq Musa, a director of Guardant Health, reported two transactions in September 2025. On 09/15/2025 249 restricted stock units (RSUs) vested, converting into 249 common shares and increasing his derivative/underlying holdings. On 09/17/2025 he sold 116 common shares at $55.63 per share, reducing his direct common stock holdings from 7,707 to 7,591 shares. After these transactions, he beneficially owns 7,591 common shares directly and 4,498 shares underlying RSUs.
Myrtle S. Potter, a director of Guardant Health, Inc. (GH), reported an RSU vesting and a subsequent small sale of shares. On 09/15/2025 a restricted stock unit award vested for 68 shares at no cash price. Two days later, on 09/17/2025, the reporting person sold 26 shares at $55.63 per share. Beneficial ownership reported after the sale was 18,281 shares on a direct basis. The filing was executed by attorney-in-fact John G. Saia on 09/17/2025. The RSU award follows a vesting schedule that began with 25% vesting on October 15, 2022, with the remaining 75% vesting monthly over the following three years.
Guardant Health director and Chief Legal Officer John G. Saia reported transactions on Form 4 showing equity activity dated 09/15/2025. The filing discloses that 1,019 restricted stock units vested and were converted into 1,019 shares, of which the company retained a portion to satisfy tax withholding (the filing states the retained amount equaled the tax liability). Also on 09/15/2025 Mr. Saia sold 535 shares at $54.79 per share. After these transactions he beneficially owned 45,432 shares of Guardant Health common stock.
Insider stock changes at Guardant Health (GH): On 09/15/2025 Chief Information Officer Kumud Kalia had 638 restricted stock units vest, resulting in 638 shares issued to her and retained 324 shares that were sold to satisfy tax withholding at a price of $54.79 per share. After these transactions Kalia beneficially owns 19,164 shares of Common Stock. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Chris Freeman, Chief Commercial Officer of Guardant Health (GH), reported insider transactions dated 09/15/2025. The filing shows 1,402 restricted stock units vested and were treated as an acquisition at $0, increasing his beneficial ownership to 50,223 shares before subsequent disposition. The company retained 1,402 shares to satisfy tax withholding related to the vesting. Separately, Freeman disposed of 594 shares at $54.79, leaving him with 49,629 shares beneficially owned after the reported transactions.
Craig Eagle, Chief Medical Officer of Guardant Health, reported transactions on 09/15/2025 related to the vesting of restricted stock units (RSUs) granted June 9, 2023. A tranche of 1,402 shares vested and were delivered at no cash price to the reporting person. To satisfy tax withholding obligations, the company retained 711 shares at an effective withholding price of $54.79 per share.
After these transactions the reporting person beneficially owned 37,482 shares of Guardant Health common stock. The RSU award vests over three years (33% vested June 15, 2024; remaining 67% vests in equal quarterly installments over the following two years). The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Michael Brian Bell, Chief Financial Officer of Guardant Health, reported changes in his beneficial ownership on 09/15/2025. He received two installments of restricted stock units that resulted in 1,233 and 2,039 common shares being issued (transaction codes M) and the company retained 1,233 shares to cover tax withholding. He sold 1,659 shares at $54.79 (transaction code F). Following these transactions he beneficially owned 46,300 shares.
Guardant Health, Inc. (GH) Form 144 reports a proposed sale of 26 common shares by a person associated with the issuer, to be executed approximately on 09/17/2025 through Charles Schwab & Co., Inc. The shares arose from a restricted stock lapse on 09/15/2025 and were issued as equity compensation. The filing lists 26 shares outstanding to be sold with an aggregate market value shown as $1,446.00 and total company shares outstanding at 124,705,857. The form also discloses three prior small sales by the same seller of 26 shares each on 06/18/2025, 07/17/2025, and 08/19/2025 with gross proceeds of $1,286, $1,253, and $1,535 respectively.
Form 144 notice for Guardant Health, Inc. (GH) shows an intended sale of 116 common shares via Charles Schwab on 09/17/2025 with an aggregate market value of $6,453. The shares were acquired on 09/15/2025 through a restricted stock lapse under equity compensation. The filing lists prior open-market sales by the same account in the past three months: 3,213 shares for $158,947 on 06/18/2025, and two smaller sales of 116 shares$5,591 and $6,846 on 07/17/2025 and 08/19/2025, respectively. The signer affirms no undisclosed material adverse information.